Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Adverum Biotechnologies Inc
ADVMCurrent price
4.29 USD
-0.41 USD (-8.72%)
Last closed
4.66 USD
Company
www.adverum.com
ISIN
US00773U1088
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
109 421 152 USD
Yield for 12 month
-46.40 %
1Y
3Y
5Y
10Y
15Y
ADVM
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Address: 100 Cardinal Way, Redwood City, CA, United States, 94063
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
29.71 USDP/E ratio
–Dividend Yield
–Current Year
+3 600 000 USD
Last Year
+3 600 000 USD
Current Quarter
+1 000 000 USD
Last Quarter
–
Current Year
-2 044 000 USD
Last Year
-6 528 000 USD
Current Quarter
+110 000 USD
Last Quarter
-956 000 USD
Key Figures ADVM
1 year
3 years
5 years
10 years
EBITDA
-99 024 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-29.83 %
PEG Ratio
–
Return On Equity TTM
-76.26 %
Wall Street Target Price
29.71 USD
Revenue TTM
1 000 000 USD
Book Value
6.93 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-70.00 %
Dividend Yield
–
Gross Profit TTM
-81 681 000 USD
Earnings per share
-5.95 USD
Diluted Eps TTM
-5.95 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ADVM
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History ADVM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
21.03.2024
Dividend Date
–
Stock Valuation ADVM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
29.44
Price Sales TTM
109.42
Enterprise Value EBITDA
0.099
Price Book MRQ
0.76
Financials ADVM
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ADVM
For 52 weeks
4.97 USD
29.70 USD
50 Day MA
7.13 USD
Shares Short Prior Month
1 527 111
200 Day MA
8.84 USD
Short Ratio
5.53
Shares Short
1 357 223
Short Percent
6.57 %
BeatStart